← board
CDIO
distress 4/10 · elevated risk$1.65-2%today-75% from 52w high
Revenue
pre-revenue
Liquidity
$0M
Runway
—
Shares 1y
+68%
Price & events
-16.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.6%
1D
-2.2%
1W
-24.9%
1M
-9.2%
3M
-14.8%
6M
-62.5%
1Y
-89.1%
2Y
—
5Y
-99.4%
All
Overview
- Market Cap
- $4.89M
- Volume
- 3.82K
- 52 Week Range
- $1.05 – $6.55
- Total Shares
- 2.96M
- Float Shares
- 2.83M
- Short %
- 0.68%
- % Held by Insiders
- 8.31%
- % Held by Institutions
- 9.34%
- RVOL
- 0.12x
- Beta
- 2.18
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 2
- 2026-08-13earningsEarningsEarnings releaseyahoo
- 2025-05-28fda agreementRegained compliance with Nasdaq minimum bid price ruleSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 2,959,469 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2024-08-27BenchmarkSpeculative Buy
Competitors
- none identified
Recent news
- 2026-07-16Cardio Diagnostics Leverages AI and Precision Medicine to Address Growing Cardiovascular Disease Market - citybuzz -
- 2026-07-14Price to book forward of Cardio Diagnostics Holdings Inc. – NASDAQ:CDIOW - TradingView
- 2026-07-13Cardio Diagnostics (NASDAQ: CDIO) eyes private share issuance of up to $10M - Stock Titan
- 2026-07-03CDIO Should I Buy - Intellectia AI
- 2026-07-02Cardio Diagnostics (CDIO) director receives 2,854 stock options at $2.19 - Stock Titan
- 2026-07-02Cardio Diagnostics (CDIO) director receives 2,854 stock options at $2.19 strike - Stock Titan
- 2026-07-01CDIO Q1 2025 Earnings: EPS Beats Estimates by 47.2% as Company Advances Diagnostic Platform - Analyst Coverage Count - dars.gov.et
- 2026-07-01Cardio Diagnostics Holdings (NASDAQ: CDIO) Showcases Precision Cardiovascular Solutions for Employers, Health Plans - The Globe and Mail
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.